334 related articles for article (PubMed ID: 35729608)
1. Novel applications of molecular imaging to guide breast cancer therapy.
Edmonds CE; O'Brien SR; Mankoff DA; Pantel AR
Cancer Imaging; 2022 Jun; 22(1):31. PubMed ID: 35729608
[TBL] [Abstract][Full Text] [Related]
2. Molecular Imaging and Precision Medicine in Breast Cancer.
Chudgar AV; Mankoff DA
PET Clin; 2017 Jan; 12(1):39-51. PubMed ID: 27863565
[TBL] [Abstract][Full Text] [Related]
3. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
4. Molecular imaging of breast cancer.
Oude Munnink TH; Nagengast WB; Brouwers AH; Schröder CP; Hospers GA; Lub-de Hooge MN; van der Wall E; van Diest PJ; de Vries EG
Breast; 2009 Oct; 18 Suppl 3():S66-73. PubMed ID: 19914546
[TBL] [Abstract][Full Text] [Related]
5. Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-DGlucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective.
Sager O; Dincoglan F; Demiral S; Uysal B; Gamsiz H; Elcim Y; Gundem E; Dirican B; Beyzadeoglu M
Curr Radiopharm; 2019; 12(1):4-10. PubMed ID: 30465520
[TBL] [Abstract][Full Text] [Related]
6.
Romine PE; Peterson LM; Kurland BF; Byrd DW; Novakova-Jiresova A; Muzi M; Specht JM; Doot RK; Link JM; Krohn KA; Kinahan PE; Mankoff DA; Linden HM
Breast Cancer Res; 2021 Aug; 23(1):88. PubMed ID: 34425871
[TBL] [Abstract][Full Text] [Related]
7. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
[TBL] [Abstract][Full Text] [Related]
8. PET in breast cancer.
Flanagan FL; Dehdashti F; Siegel BA
Semin Nucl Med; 1998 Oct; 28(4):290-302. PubMed ID: 9800236
[TBL] [Abstract][Full Text] [Related]
9. Molecular imaging using PET for breast cancer.
Kurihara H; Shimizu C; Miyakita Y; Yoshida M; Hamada A; Kanayama Y; Yonemori K; Hashimoto J; Tani H; Kodaira M; Yunokawa M; Yamamoto H; Watanabe Y; Fujiwara Y; Tamura K
Breast Cancer; 2016 Jan; 23(1):24-32. PubMed ID: 25917108
[TBL] [Abstract][Full Text] [Related]
10. Molecular Imaging Assessment of Hormonally Sensitive Breast Cancer: An Appraisal of 2-[18F]-Fluoro-2-Deoxy-Glucose and Newer Non-2-[18F]-Fluoro-2-Deoxy-Glucose PET Tracers.
Yadav D; Kumar R; Phulia A; Basu S; Alavi A
PET Clin; 2022 Jul; 17(3):399-413. PubMed ID: 35717099
[TBL] [Abstract][Full Text] [Related]
11. Role of positron-emission tomography scan in the diagnosis and management of breast cancer.
Almubarak M; Osman S; Marano G; Abraham J
Oncology (Williston Park); 2009 Mar; 23(3):255-61. PubMed ID: 19418826
[TBL] [Abstract][Full Text] [Related]
12. Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
Kurland BF; Peterson LM; Lee JH; Schubert EK; Currin ER; Link JM; Krohn KA; Mankoff DA; Linden HM
Clin Cancer Res; 2017 Jan; 23(2):407-415. PubMed ID: 27342400
[TBL] [Abstract][Full Text] [Related]
13. PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.
Jadvar H
J Nucl Med; 2016 Oct; 57(Suppl 3):25S-29S. PubMed ID: 27694167
[TBL] [Abstract][Full Text] [Related]
14. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
15. Imaging for illuminating actionable pathways in breast cancer.
Gilardi L; Airò Farulla LS; Ceci F
Curr Opin Oncol; 2022 Nov; 34(6):606-613. PubMed ID: 36093891
[TBL] [Abstract][Full Text] [Related]
16. Molecular Imaging of Biomarkers in Breast Cancer.
Ulaner GA; Riedl CC; Dickler MN; Jhaveri K; Pandit-Taskar N; Weber W
J Nucl Med; 2016 Feb; 57 Suppl 1(Suppl 1):53S-9S. PubMed ID: 26834103
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
18. Using nuclear medicine imaging in clinical practice: update on PET to guide treatment of patients with metastatic breast cancer.
Clark AS; McDonald E; Lynch MC; Mankoff D
Oncology (Williston Park); 2014 May; 28(5):424-30. PubMed ID: 25004657
[TBL] [Abstract][Full Text] [Related]
19. Biological characterisation of breast cancer by means of PET.
Buck AK; Schirrmeister H; Mattfeldt T; Reske SN
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S80-7. PubMed ID: 15127240
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography in diagnosis and management of invasive breast cancer: current status and future perspectives.
Wu D; Gambhir SS
Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S55-63. PubMed ID: 12756080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
